Kolkata, India

Kamal Nayan Jalan

This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 3 EPO patents. Top assignee: Ucl Business Plc. Active years: 2013-2020.


% Patents Active = 100.0


 

Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 44(Granted Patents)


Company Filing History:


Years Active: 2013-2020

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Kamal Nayan Jalan: Innovator in Hepatic Treatments

Introduction

Kamal Nayan Jalan is a prominent inventor based in Kolkata, India. He has made significant contributions to the field of medicine, particularly in the treatment of hepatic encephalopathy. With a total of 3 patents to his name, Jalan's work focuses on innovative compositions that aim to improve liver health.

Latest Patents

One of his latest patents involves compositions comprising ornithine and phenylacetate or phenylbutyrate for treating hepatic encephalopathy. This invention relates to the use of ornithine in the manufacture of a medicament that can be combined with either phenylacetate or phenylbutyrate. The goal is to prevent or treat liver decompensation or hepatic encephalopathy. Additionally, the invention also covers the use of phenylacetate and phenylbutyrate in combination with ornithine for the same therapeutic purposes.

Career Highlights

Kamal Nayan Jalan is associated with UCL Business Plc, where he continues to develop his innovative ideas. His work has garnered attention in the medical community, particularly for its potential to improve treatment options for patients suffering from liver-related conditions.

Collaborations

Jalan collaborates with Rajiv Jalan, who is also involved in the field of medical innovations. Their partnership aims to enhance the development of effective treatments for hepatic issues.

Conclusion

Kamal Nayan Jalan's contributions to the field of medicine through his patents reflect his dedication to improving liver health. His innovative approaches have the potential to make a significant impact on the treatment of hepatic encephalopathy.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…